1318 - House Plans · Title: 1318 Created Date: 2/7/2019 9:56:23 PM
HCC5-1318
description
Transcript of HCC5-1318
![Page 1: HCC5-1318](https://reader036.fdocuments.net/reader036/viewer/2022083006/56813dd2550346895da79d55/html5/thumbnails/1.jpg)
A
B
C
HCC5-1318
0
500
1000
1500
2000
2500
3000
3500
4000
4500
1 2 3 4 5 6 7 8 9 10 11 12 13 14
Tum
or vo
lum
e (m
m3)
VehicleForetinib (15mg/kg)Foretinib (30mg/kg)
Days during treatment
ForetinibVehicle(15mg/kg)
Foretinib(30mg/kg)
Fig 2S Effects of foretinib on tumor growth of patient-derived xenograft line 5-1318. 5-1318 tumors were s.c implanted in SCID mice as described in Materials and Methods. Mice bearing tumor xenografts were treated with vehicle (30% Captisol) or 2 doses of foretinib: 15 mg/kg (daily) and 30 mg/kg (every other day) for 14 days as described in Materials and Methods. Each treatment arm involved 14 independent tumor-bearing mice. Mean of tumor volume ± SE at given time points (A), representative vehicle- and foretinib-treated tumors (B) and the corresponding tumor weight and statistical analysis (C) for 5-1318 xenografts are shown. Different asterisks (*) indicate significantly different from one another at P <0.05. Experiments were repeated twice with similar results.
0
500
1000
1500
2000
2500
3000
3500
4000
Tum
or w
eigh
t (m
g)
Foretinib (mg/kg)Vehicle + - -
- 15 30
*
**